It is estimated that 38% of lung squamous cell carcinomas (LuSC) and 18% of lung adenocarcinomas (LuAD) harbor mutations in Nuclear factor erythroid 2-related factor 2 (NRF2), or its negative regulator Kelch-like ECH-associated protein 1 (KEAP1) [[1], [2], [3]], making this pathway one of the most commonly mutated in non-small cell lung cancer (NSCLC). Here, NFE2L2 is linked to lung adenocarcinoma.